PMID- 32839081
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 1873-2496 (Electronic)
IS  - 1078-1439 (Linking)
VI  - 38
IP  - 12
DP  - 2020 Dec
TI  - Efficacy and safety of apatinib monotherapy in metastatic renal cell carcinoma 
      (mRCC) patients: A single-arm observational study.
PG  - 936.e1-936.e6
LID - S1078-1439(20)30361-6 [pii]
LID - 10.1016/j.urolonc.2020.07.023 [doi]
AB  - BACKGROUND: Antiangiogenic treatments play an important role in the therapeutic 
      strategy for metastatic renal cell carcinoma. Apatinib is an oral tyrosine kinase 
      inhibitor that targets vascular endothelial growth factor receptor-2. We aimed to 
      assess the efficacy and safety of apatinib therapy in metastatic renal cell 
      carcinoma patients. METHODS: Between January 2018 and November 2018, we enrolled 
      53 metastatic renal cell carcinoma patients. Apatinib was administered at an 
      initial dose of 500 mg once daily. The disease control rate, objective response 
      rate, progression-free survival, and adverse events were reviewed and evaluated. 
      FINDINGS: Among the 53 patients, 14 achieved partial response and 31 achieved 
      stable disease. Thus, the disease control rate was 84.9% and the objective 
      response rate was 26.4%. The median progression-free survival was 11.2 months 
      (95% confidence interval: 9.884-12.574). Most of the adverse events (AEs) were at 
      grade 1 or 2, and the main grade 3 AEs were hypertension (5.7%), anemia (3.8%), 
      and thrombocytopenia (3.8%). INTERPRETATION: Apatinib showed promising efficacy 
      and manageable toxicity in metastatic renal cell carcinoma patients, giving 
      potent evidence to conduct further clinical trials.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Cui, Yan
AU  - Cui Y
AD  - Department of Urology, Harbin Medical University Cancer Hospital, Harbin, 
      Heilongjiang, P.R. China.
FAU - Cao, Yuxuan
AU  - Cao Y
AD  - Department of Urology, Harbin Medical University Cancer Hospital, Harbin, 
      Heilongjiang, P.R. China.
FAU - Cao, Muyang
AU  - Cao M
AD  - Department of Urology, Harbin Medical University Cancer Hospital, Harbin, 
      Heilongjiang, P.R. China.
FAU - Chen, Xueting
AU  - Chen X
AD  - Department of Urology, Harbin Medical University Cancer Hospital, Harbin, 
      Heilongjiang, P.R. China.
FAU - Liu, Guobin
AU  - Liu G
AD  - Department of Urology, Harbin Medical University Cancer Hospital, Harbin, 
      Heilongjiang, P.R. China.
FAU - Chen, Hui
AU  - Chen H
AD  - Department of Urology, Harbin Medical University Cancer Hospital, Harbin, 
      Heilongjiang, P.R. China. Electronic address: hmuhuichen@sina.com.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200822
PL  - United States
TA  - Urol Oncol
JT  - Urologic oncology
JID - 9805460
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/secondary
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/*pathology
MH  - Male
MH  - Middle Aged
MH  - Progression-Free Survival
MH  - Pyridines/adverse effects/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Apatinib
OT  - Efficacy
OT  - Metastatic renal cell carcinoma
OT  - Safety
OT  - Targeted therapy
EDAT- 2020/08/26 06:00
MHDA- 2021/08/06 06:00
CRDT- 2020/08/26 06:00
PHST- 2020/03/20 00:00 [received]
PHST- 2020/07/21 00:00 [revised]
PHST- 2020/07/22 00:00 [accepted]
PHST- 2020/08/26 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
PHST- 2020/08/26 06:00 [entrez]
AID - S1078-1439(20)30361-6 [pii]
AID - 10.1016/j.urolonc.2020.07.023 [doi]
PST - ppublish
SO  - Urol Oncol. 2020 Dec;38(12):936.e1-936.e6. doi: 10.1016/j.urolonc.2020.07.023. 
      Epub 2020 Aug 22.